{"id":3694,"date":"2026-09-07T18:04:22","date_gmt":"2026-09-07T18:04:22","guid":{"rendered":"https:\/\/indiamedicine.org\/?p=3694"},"modified":"2026-09-07T18:04:22","modified_gmt":"2026-09-07T18:04:22","slug":"piyush-goyal-indian-pharma-beyond-generics-2026","status":"publish","type":"post","link":"https:\/\/indiamedicine.org\/?p=3694","title":{"rendered":"Piyush Goyal Urges Indian Pharma to Move Beyond Generics into High-Value Medicines"},"content":{"rendered":"\n\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Pharma Ambition<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Minister Goyal&#8217;s remarks at the Bharat Health Global Expo 2026 fit within a broader pattern of government statements throughout 2026 emphasizing India&#8217;s ambition to become a comprehensive global pharmaceutical powerhouse \u2014 not just a generic drug supplier. Earlier in the year, the Minister stated that India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, as reported by Express Pharma in June 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The government&#8217;s focus areas include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Research and development investment<\/strong> \u2014 encouraging domestic companies to move from reverse-engineering to original drug discovery.<\/li>\n<li><strong>Biosimilars and biologics<\/strong> \u2014 building manufacturing and regulatory capacity for complex biological products.<\/li>\n<li><strong>Global market access<\/strong> \u2014 pursuing bilateral trade relationships and export promotion through platforms like iPHEX and Pharmexcil initiatives.<\/li>\n<li><strong>Regulatory modernization<\/strong> \u2014 the CDSCO&#8217;s ongoing digital platform development and the 2026 NDCT Rules amendments both signal a regulator moving toward efficiency and transparency alongside safety.<\/li>\n<\/ul>\n\n\n\n\n<h2 class=\"wp-block-heading\">&#x2705; Practical Checklist for Pharma Buyers<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">In light of this strategic shift, buyers of Indian pharmaceutical products should:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>&#x2705; <strong>Maintain current generic sourcing relationships<\/strong> \u2014 India&#8217;s generic manufacturing base remains robust and reliable for the foreseeable future.<\/li>\n<li>&#x2705; <strong>Explore complex generic and biologic offerings<\/strong> \u2014 as Indian manufacturers expand into these segments, evaluate new suppliers against your specific therapeutic needs.<\/li>\n<li>&#x2705; <strong>Verify WHO-GMP and CDSCO compliance<\/strong> for every supplier and every product, regardless of category complexity.<\/li>\n<li>&#x2705; <strong>Monitor regulatory developments<\/strong> \u2014 the CDSCO&#8217;s digital platform initiative, NDCT reforms, and Schedule M updates all affect the quality assurance landscape.<\/li>\n<li>&#x2705; <strong>Request up-to-date documentation<\/strong> \u2014 manufacturing licenses, stability data, audit records, and product-specific approvals should be current and verifiable.<\/li>\n<li>&#x2705; <strong>Work with verified distributors<\/strong> \u2014 for a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Sources: Pharmabiz.com (September 7, 2026) \u2014 &#8220;India must build on its strength in generics to become a global leader in complex &amp; high-value medicines&#8221;; DD India (September 7, 2026) \u2014 &#8220;India&#8217;s Pharma Sector Must Go Beyond Generics, Pursue R&amp;D and Innovation&#8221;; Express Pharma (June 9, 2026) \u2014 Piyush Goyal USD 120 billion pharma sector target by 2031. Details sourced via Google News RSS as of September 8, 2026.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f48e; What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international procurement professionals and healthcare buyers who source from India, this strategic pivot carries several practical implications:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Short-term stability in generic supply.<\/strong> India&#8217;s core generic medicine manufacturing capability is not disappearing \u2014 it remains a cornerstone of the industry and the primary source of affordable medicines for global health programs. Buyers should expect continuity in the near term.<\/li>\n<li><strong>Gradual expansion of product complexity.<\/strong> Over the medium to long term, Indian suppliers are likely to offer an increasingly broad portfolio that includes complex generics (such as injectables, oncology products, and transdermal formulations) alongside traditional oral solids. Buyers may find new sourcing opportunities in these higher-value categories.<\/li>\n<li><strong>Verify quality at every level.<\/strong> As product complexity increases, so does the importance of robust quality verification. WHO-GMP certification, CDSCO regulatory compliance, and documented manufacturing standards become even more critical when sourcing complex formulations. Buyers should maintain rigorous due diligence regardless of product category.<\/li>\n<li><strong>Engage with the evolving landscape.<\/strong> The transition toward innovation-driven pharma is a multi-year trajectory. Buyers who stay informed about regulatory changes, manufacturing capability upgrades, and new product approvals from Indian suppliers will be better positioned to make strategic sourcing decisions.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Pharma Ambition<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Minister Goyal&#8217;s remarks at the Bharat Health Global Expo 2026 fit within a broader pattern of government statements throughout 2026 emphasizing India&#8217;s ambition to become a comprehensive global pharmaceutical powerhouse \u2014 not just a generic drug supplier. Earlier in the year, the Minister stated that India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, as reported by Express Pharma in June 2026.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The government&#8217;s focus areas include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Research and development investment<\/strong> \u2014 encouraging domestic companies to move from reverse-engineering to original drug discovery.<\/li>\n<li><strong>Biosimilars and biologics<\/strong> \u2014 building manufacturing and regulatory capacity for complex biological products.<\/li>\n<li><strong>Global market access<\/strong> \u2014 pursuing bilateral trade relationships and export promotion through platforms like iPHEX and Pharmexcil initiatives.<\/li>\n<li><strong>Regulatory modernization<\/strong> \u2014 the CDSCO&#8217;s ongoing digital platform development and the 2026 NDCT Rules amendments both signal a regulator moving toward efficiency and transparency alongside safety.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x2705; Practical Checklist for Pharma Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>In light of this strategic shift, buyers of Indian pharmaceutical products should:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>&#x2705; <strong>Maintain current generic sourcing relationships<\/strong> \u2014 India&#8217;s generic manufacturing base remains robust and reliable for the foreseeable future.<\/li>\n<li>&#x2705; <strong>Explore complex generic and biologic offerings<\/strong> \u2014 as Indian manufacturers expand into these segments, evaluate new suppliers against your specific therapeutic needs.<\/li>\n<li>&#x2705; <strong>Verify WHO-GMP and CDSCO compliance<\/strong> for every supplier and every product, regardless of category complexity.<\/li>\n<li>&#x2705; <strong>Monitor regulatory developments<\/strong> \u2014 the CDSCO&#8217;s digital platform initiative, NDCT reforms, and Schedule M updates all affect the quality assurance landscape.<\/li>\n<li>&#x2705; <strong>Request up-to-date documentation<\/strong> \u2014 manufacturing licenses, stability data, audit records, and product-specific approvals should be current and verifiable.<\/li>\n<li>&#x2705; <strong>Work with verified distributors<\/strong> \u2014 for a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: Pharmabiz.com (September 7, 2026) \u2014 &#8220;India must build on its strength in generics to become a global leader in complex &amp; high-value medicines&#8221;; DD India (September 7, 2026) \u2014 &#8220;India&#8217;s Pharma Sector Must Go Beyond Generics, Pursue R&amp;D and Innovation&#8221;; Express Pharma (June 9, 2026) \u2014 Piyush Goyal USD 120 billion pharma sector target by 2031. Details sourced via Google News RSS as of September 8, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4ca; Why This Shift Matters<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The push toward high-value pharmaceutical products reflects several converging pressures and opportunities:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Global pricing pressure on simple generics.<\/strong> Competitive manufacturing from multiple countries has compressed margins on basic oral solid generics, the segment where India has historically been strongest.<\/li>\n<li><strong>Rising complexity of patient needs.<\/strong> Aging populations and increasing prevalence of chronic and specialty conditions drive demand for biologic therapies, targeted treatments, and complex dosage forms \u2014 areas where India currently has limited market share.<\/li>\n<li><strong>India&#8217;s inherent strengths.<\/strong> The country possesses a large pool of scientific talent, an established API (Active Pharmaceutical Ingredient) manufacturing base, and a regulatory framework that is actively modernizing \u2014 all prerequisites for a transition to higher-value products.<\/li>\n<li><strong>Government policy direction.<\/strong> The Commerce Ministry&#8217;s emphasis on R&amp;D and innovation signals that policy support, incentives, and regulatory facilitation may increasingly favor companies investing in complex and high-value pharmaceutical segments.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f48e; What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international procurement professionals and healthcare buyers who source from India, this strategic pivot carries several practical implications:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Short-term stability in generic supply.<\/strong> India&#8217;s core generic medicine manufacturing capability is not disappearing \u2014 it remains a cornerstone of the industry and the primary source of affordable medicines for global health programs. Buyers should expect continuity in the near term.<\/li>\n<li><strong>Gradual expansion of product complexity.<\/strong> Over the medium to long term, Indian suppliers are likely to offer an increasingly broad portfolio that includes complex generics (such as injectables, oncology products, and transdermal formulations) alongside traditional oral solids. Buyers may find new sourcing opportunities in these higher-value categories.<\/li>\n<li><strong>Verify quality at every level.<\/strong> As product complexity increases, so does the importance of robust quality verification. WHO-GMP certification, CDSCO regulatory compliance, and documented manufacturing standards become even more critical when sourcing complex formulations. Buyers should maintain rigorous due diligence regardless of product category.<\/li>\n<li><strong>Engage with the evolving landscape.<\/strong> The transition toward innovation-driven pharma is a multi-year trajectory. Buyers who stay informed about regulatory changes, manufacturing capability upgrades, and new product approvals from Indian suppliers will be better positioned to make strategic sourcing decisions.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Pharma Ambition<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Minister Goyal&#8217;s remarks at the Bharat Health Global Expo 2026 fit within a broader pattern of government statements throughout 2026 emphasizing India&#8217;s ambition to become a comprehensive global pharmaceutical powerhouse \u2014 not just a generic drug supplier. Earlier in the year, the Minister stated that India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, as reported by Express Pharma in June 2026.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The government&#8217;s focus areas include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Research and development investment<\/strong> \u2014 encouraging domestic companies to move from reverse-engineering to original drug discovery.<\/li>\n<li><strong>Biosimilars and biologics<\/strong> \u2014 building manufacturing and regulatory capacity for complex biological products.<\/li>\n<li><strong>Global market access<\/strong> \u2014 pursuing bilateral trade relationships and export promotion through platforms like iPHEX and Pharmexcil initiatives.<\/li>\n<li><strong>Regulatory modernization<\/strong> \u2014 the CDSCO&#8217;s ongoing digital platform development and the 2026 NDCT Rules amendments both signal a regulator moving toward efficiency and transparency alongside safety.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x2705; Practical Checklist for Pharma Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>In light of this strategic shift, buyers of Indian pharmaceutical products should:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>&#x2705; <strong>Maintain current generic sourcing relationships<\/strong> \u2014 India&#8217;s generic manufacturing base remains robust and reliable for the foreseeable future.<\/li>\n<li>&#x2705; <strong>Explore complex generic and biologic offerings<\/strong> \u2014 as Indian manufacturers expand into these segments, evaluate new suppliers against your specific therapeutic needs.<\/li>\n<li>&#x2705; <strong>Verify WHO-GMP and CDSCO compliance<\/strong> for every supplier and every product, regardless of category complexity.<\/li>\n<li>&#x2705; <strong>Monitor regulatory developments<\/strong> \u2014 the CDSCO&#8217;s digital platform initiative, NDCT reforms, and Schedule M updates all affect the quality assurance landscape.<\/li>\n<li>&#x2705; <strong>Request up-to-date documentation<\/strong> \u2014 manufacturing licenses, stability data, audit records, and product-specific approvals should be current and verifiable.<\/li>\n<li>&#x2705; <strong>Work with verified distributors<\/strong> \u2014 for a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: Pharmabiz.com (September 7, 2026) \u2014 &#8220;India must build on its strength in generics to become a global leader in complex &amp; high-value medicines&#8221;; DD India (September 7, 2026) \u2014 &#8220;India&#8217;s Pharma Sector Must Go Beyond Generics, Pursue R&amp;D and Innovation&#8221;; Express Pharma (June 9, 2026) \u2014 Piyush Goyal USD 120 billion pharma sector target by 2031. Details sourced via Google News RSS as of September 8, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f3af; The Core Message: Beyond Generics<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Minister Goyal&#8217;s central directive to the Indian pharmaceutical industry was clear: the era of relying predominantly on low-cost generic drug exports is giving way to a more ambitious trajectory. India must leverage its established manufacturing base and talent pool to move up the value chain \u2014 into complex generics, biosimilars, specialty biologics, and deep R&amp;D-driven drug discovery.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4ca; Why This Shift Matters<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The push toward high-value pharmaceutical products reflects several converging pressures and opportunities:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Global pricing pressure on simple generics.<\/strong> Competitive manufacturing from multiple countries has compressed margins on basic oral solid generics, the segment where India has historically been strongest.<\/li>\n<li><strong>Rising complexity of patient needs.<\/strong> Aging populations and increasing prevalence of chronic and specialty conditions drive demand for biologic therapies, targeted treatments, and complex dosage forms \u2014 areas where India currently has limited market share.<\/li>\n<li><strong>India&#8217;s inherent strengths.<\/strong> The country possesses a large pool of scientific talent, an established API (Active Pharmaceutical Ingredient) manufacturing base, and a regulatory framework that is actively modernizing \u2014 all prerequisites for a transition to higher-value products.<\/li>\n<li><strong>Government policy direction.<\/strong> The Commerce Ministry&#8217;s emphasis on R&amp;D and innovation signals that policy support, incentives, and regulatory facilitation may increasingly favor companies investing in complex and high-value pharmaceutical segments.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f48e; What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international procurement professionals and healthcare buyers who source from India, this strategic pivot carries several practical implications:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Short-term stability in generic supply.<\/strong> India&#8217;s core generic medicine manufacturing capability is not disappearing \u2014 it remains a cornerstone of the industry and the primary source of affordable medicines for global health programs. Buyers should expect continuity in the near term.<\/li>\n<li><strong>Gradual expansion of product complexity.<\/strong> Over the medium to long term, Indian suppliers are likely to offer an increasingly broad portfolio that includes complex generics (such as injectables, oncology products, and transdermal formulations) alongside traditional oral solids. Buyers may find new sourcing opportunities in these higher-value categories.<\/li>\n<li><strong>Verify quality at every level.<\/strong> As product complexity increases, so does the importance of robust quality verification. WHO-GMP certification, CDSCO regulatory compliance, and documented manufacturing standards become even more critical when sourcing complex formulations. Buyers should maintain rigorous due diligence regardless of product category.<\/li>\n<li><strong>Engage with the evolving landscape.<\/strong> The transition toward innovation-driven pharma is a multi-year trajectory. Buyers who stay informed about regulatory changes, manufacturing capability upgrades, and new product approvals from Indian suppliers will be better positioned to make strategic sourcing decisions.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Pharma Ambition<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Minister Goyal&#8217;s remarks at the Bharat Health Global Expo 2026 fit within a broader pattern of government statements throughout 2026 emphasizing India&#8217;s ambition to become a comprehensive global pharmaceutical powerhouse \u2014 not just a generic drug supplier. Earlier in the year, the Minister stated that India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, as reported by Express Pharma in June 2026.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The government&#8217;s focus areas include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Research and development investment<\/strong> \u2014 encouraging domestic companies to move from reverse-engineering to original drug discovery.<\/li>\n<li><strong>Biosimilars and biologics<\/strong> \u2014 building manufacturing and regulatory capacity for complex biological products.<\/li>\n<li><strong>Global market access<\/strong> \u2014 pursuing bilateral trade relationships and export promotion through platforms like iPHEX and Pharmexcil initiatives.<\/li>\n<li><strong>Regulatory modernization<\/strong> \u2014 the CDSCO&#8217;s ongoing digital platform development and the 2026 NDCT Rules amendments both signal a regulator moving toward efficiency and transparency alongside safety.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x2705; Practical Checklist for Pharma Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>In light of this strategic shift, buyers of Indian pharmaceutical products should:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>&#x2705; <strong>Maintain current generic sourcing relationships<\/strong> \u2014 India&#8217;s generic manufacturing base remains robust and reliable for the foreseeable future.<\/li>\n<li>&#x2705; <strong>Explore complex generic and biologic offerings<\/strong> \u2014 as Indian manufacturers expand into these segments, evaluate new suppliers against your specific therapeutic needs.<\/li>\n<li>&#x2705; <strong>Verify WHO-GMP and CDSCO compliance<\/strong> for every supplier and every product, regardless of category complexity.<\/li>\n<li>&#x2705; <strong>Monitor regulatory developments<\/strong> \u2014 the CDSCO&#8217;s digital platform initiative, NDCT reforms, and Schedule M updates all affect the quality assurance landscape.<\/li>\n<li>&#x2705; <strong>Request up-to-date documentation<\/strong> \u2014 manufacturing licenses, stability data, audit records, and product-specific approvals should be current and verifiable.<\/li>\n<li>&#x2705; <strong>Work with verified distributors<\/strong> \u2014 for a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: Pharmabiz.com (September 7, 2026) \u2014 &#8220;India must build on its strength in generics to become a global leader in complex &amp; high-value medicines&#8221;; DD India (September 7, 2026) \u2014 &#8220;India&#8217;s Pharma Sector Must Go Beyond Generics, Pursue R&amp;D and Innovation&#8221;; Express Pharma (June 9, 2026) \u2014 Piyush Goyal USD 120 billion pharma sector target by 2031. Details sourced via Google News RSS as of September 8, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4f0; The Event: Bharat Health Global Expo 2026<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The Bharat Health Global Expo 2026 was inaugurated by Union Commerce and Industry Minister Piyush Goyal at Bharat Mandapam in New Delhi on September 7, 2026. The event brings together India&#8217;s healthcare and life-sciences capabilities onto a single platform for international collaboration, as reported by <strong>Pharmabiz.com<\/strong> and <strong>DD India<\/strong> on September 7, 2026.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The expo serves as a nexus for pharmaceutical manufacturers, biotechnology firms, medical device producers, and healthcare service providers to connect with global partners, investors, and procurement heads from regulated and emerging markets.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f3af; The Core Message: Beyond Generics<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Minister Goyal&#8217;s central directive to the Indian pharmaceutical industry was clear: the era of relying predominantly on low-cost generic drug exports is giving way to a more ambitious trajectory. India must leverage its established manufacturing base and talent pool to move up the value chain \u2014 into complex generics, biosimilars, specialty biologics, and deep R&amp;D-driven drug discovery.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4ca; Why This Shift Matters<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The push toward high-value pharmaceutical products reflects several converging pressures and opportunities:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Global pricing pressure on simple generics.<\/strong> Competitive manufacturing from multiple countries has compressed margins on basic oral solid generics, the segment where India has historically been strongest.<\/li>\n<li><strong>Rising complexity of patient needs.<\/strong> Aging populations and increasing prevalence of chronic and specialty conditions drive demand for biologic therapies, targeted treatments, and complex dosage forms \u2014 areas where India currently has limited market share.<\/li>\n<li><strong>India&#8217;s inherent strengths.<\/strong> The country possesses a large pool of scientific talent, an established API (Active Pharmaceutical Ingredient) manufacturing base, and a regulatory framework that is actively modernizing \u2014 all prerequisites for a transition to higher-value products.<\/li>\n<li><strong>Government policy direction.<\/strong> The Commerce Ministry&#8217;s emphasis on R&amp;D and innovation signals that policy support, incentives, and regulatory facilitation may increasingly favor companies investing in complex and high-value pharmaceutical segments.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f48e; What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international procurement professionals and healthcare buyers who source from India, this strategic pivot carries several practical implications:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Short-term stability in generic supply.<\/strong> India&#8217;s core generic medicine manufacturing capability is not disappearing \u2014 it remains a cornerstone of the industry and the primary source of affordable medicines for global health programs. Buyers should expect continuity in the near term.<\/li>\n<li><strong>Gradual expansion of product complexity.<\/strong> Over the medium to long term, Indian suppliers are likely to offer an increasingly broad portfolio that includes complex generics (such as injectables, oncology products, and transdermal formulations) alongside traditional oral solids. Buyers may find new sourcing opportunities in these higher-value categories.<\/li>\n<li><strong>Verify quality at every level.<\/strong> As product complexity increases, so does the importance of robust quality verification. WHO-GMP certification, CDSCO regulatory compliance, and documented manufacturing standards become even more critical when sourcing complex formulations. Buyers should maintain rigorous due diligence regardless of product category.<\/li>\n<li><strong>Engage with the evolving landscape.<\/strong> The transition toward innovation-driven pharma is a multi-year trajectory. Buyers who stay informed about regulatory changes, manufacturing capability upgrades, and new product approvals from Indian suppliers will be better positioned to make strategic sourcing decisions.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Pharma Ambition<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Minister Goyal&#8217;s remarks at the Bharat Health Global Expo 2026 fit within a broader pattern of government statements throughout 2026 emphasizing India&#8217;s ambition to become a comprehensive global pharmaceutical powerhouse \u2014 not just a generic drug supplier. Earlier in the year, the Minister stated that India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, as reported by Express Pharma in June 2026.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The government&#8217;s focus areas include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Research and development investment<\/strong> \u2014 encouraging domestic companies to move from reverse-engineering to original drug discovery.<\/li>\n<li><strong>Biosimilars and biologics<\/strong> \u2014 building manufacturing and regulatory capacity for complex biological products.<\/li>\n<li><strong>Global market access<\/strong> \u2014 pursuing bilateral trade relationships and export promotion through platforms like iPHEX and Pharmexcil initiatives.<\/li>\n<li><strong>Regulatory modernization<\/strong> \u2014 the CDSCO&#8217;s ongoing digital platform development and the 2026 NDCT Rules amendments both signal a regulator moving toward efficiency and transparency alongside safety.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x2705; Practical Checklist for Pharma Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>In light of this strategic shift, buyers of Indian pharmaceutical products should:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>&#x2705; <strong>Maintain current generic sourcing relationships<\/strong> \u2014 India&#8217;s generic manufacturing base remains robust and reliable for the foreseeable future.<\/li>\n<li>&#x2705; <strong>Explore complex generic and biologic offerings<\/strong> \u2014 as Indian manufacturers expand into these segments, evaluate new suppliers against your specific therapeutic needs.<\/li>\n<li>&#x2705; <strong>Verify WHO-GMP and CDSCO compliance<\/strong> for every supplier and every product, regardless of category complexity.<\/li>\n<li>&#x2705; <strong>Monitor regulatory developments<\/strong> \u2014 the CDSCO&#8217;s digital platform initiative, NDCT reforms, and Schedule M updates all affect the quality assurance landscape.<\/li>\n<li>&#x2705; <strong>Request up-to-date documentation<\/strong> \u2014 manufacturing licenses, stability data, audit records, and product-specific approvals should be current and verifiable.<\/li>\n<li>&#x2705; <strong>Work with verified distributors<\/strong> \u2014 for a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: Pharmabiz.com (September 7, 2026) \u2014 &#8220;India must build on its strength in generics to become a global leader in complex &amp; high-value medicines&#8221;; DD India (September 7, 2026) \u2014 &#8220;India&#8217;s Pharma Sector Must Go Beyond Generics, Pursue R&amp;D and Innovation&#8221;; Express Pharma (June 9, 2026) \u2014 Piyush Goyal USD 120 billion pharma sector target by 2031. Details sourced via Google News RSS as of September 8, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:heading --><!-- wp:post-content --><!-- wp:paragraph -->\n<p>India&#8217;s pharmaceutical sector must evolve beyond its traditional strength in generic medicines and build capabilities in complex generics, biologics, and research-driven drug development \u2014 that was the core message from Commerce and Industry Minister <strong>Piyush Goyal<\/strong> at the <strong>Bharat Health Global Expo 2026<\/strong> in New Delhi on September 7, 2026.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4f0; The Event: Bharat Health Global Expo 2026<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The Bharat Health Global Expo 2026 was inaugurated by Union Commerce and Industry Minister Piyush Goyal at Bharat Mandapam in New Delhi on September 7, 2026. The event brings together India&#8217;s healthcare and life-sciences capabilities onto a single platform for international collaboration, as reported by <strong>Pharmabiz.com<\/strong> and <strong>DD India<\/strong> on September 7, 2026.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The expo serves as a nexus for pharmaceutical manufacturers, biotechnology firms, medical device producers, and healthcare service providers to connect with global partners, investors, and procurement heads from regulated and emerging markets.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f3af; The Core Message: Beyond Generics<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Minister Goyal&#8217;s central directive to the Indian pharmaceutical industry was clear: the era of relying predominantly on low-cost generic drug exports is giving way to a more ambitious trajectory. India must leverage its established manufacturing base and talent pool to move up the value chain \u2014 into complex generics, biosimilars, specialty biologics, and deep R&amp;D-driven drug discovery.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4ca; Why This Shift Matters<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The push toward high-value pharmaceutical products reflects several converging pressures and opportunities:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Global pricing pressure on simple generics.<\/strong> Competitive manufacturing from multiple countries has compressed margins on basic oral solid generics, the segment where India has historically been strongest.<\/li>\n<li><strong>Rising complexity of patient needs.<\/strong> Aging populations and increasing prevalence of chronic and specialty conditions drive demand for biologic therapies, targeted treatments, and complex dosage forms \u2014 areas where India currently has limited market share.<\/li>\n<li><strong>India&#8217;s inherent strengths.<\/strong> The country possesses a large pool of scientific talent, an established API (Active Pharmaceutical Ingredient) manufacturing base, and a regulatory framework that is actively modernizing \u2014 all prerequisites for a transition to higher-value products.<\/li>\n<li><strong>Government policy direction.<\/strong> The Commerce Ministry&#8217;s emphasis on R&amp;D and innovation signals that policy support, incentives, and regulatory facilitation may increasingly favor companies investing in complex and high-value pharmaceutical segments.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f48e; What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international procurement professionals and healthcare buyers who source from India, this strategic pivot carries several practical implications:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Short-term stability in generic supply.<\/strong> India&#8217;s core generic medicine manufacturing capability is not disappearing \u2014 it remains a cornerstone of the industry and the primary source of affordable medicines for global health programs. Buyers should expect continuity in the near term.<\/li>\n<li><strong>Gradual expansion of product complexity.<\/strong> Over the medium to long term, Indian suppliers are likely to offer an increasingly broad portfolio that includes complex generics (such as injectables, oncology products, and transdermal formulations) alongside traditional oral solids. Buyers may find new sourcing opportunities in these higher-value categories.<\/li>\n<li><strong>Verify quality at every level.<\/strong> As product complexity increases, so does the importance of robust quality verification. WHO-GMP certification, CDSCO regulatory compliance, and documented manufacturing standards become even more critical when sourcing complex formulations. Buyers should maintain rigorous due diligence regardless of product category.<\/li>\n<li><strong>Engage with the evolving landscape.<\/strong> The transition toward innovation-driven pharma is a multi-year trajectory. Buyers who stay informed about regulatory changes, manufacturing capability upgrades, and new product approvals from Indian suppliers will be better positioned to make strategic sourcing decisions.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Pharma Ambition<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Minister Goyal&#8217;s remarks at the Bharat Health Global Expo 2026 fit within a broader pattern of government statements throughout 2026 emphasizing India&#8217;s ambition to become a comprehensive global pharmaceutical powerhouse \u2014 not just a generic drug supplier. Earlier in the year, the Minister stated that India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, as reported by Express Pharma in June 2026.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>The government&#8217;s focus areas include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Research and development investment<\/strong> \u2014 encouraging domestic companies to move from reverse-engineering to original drug discovery.<\/li>\n<li><strong>Biosimilars and biologics<\/strong> \u2014 building manufacturing and regulatory capacity for complex biological products.<\/li>\n<li><strong>Global market access<\/strong> \u2014 pursuing bilateral trade relationships and export promotion through platforms like iPHEX and Pharmexcil initiatives.<\/li>\n<li><strong>Regulatory modernization<\/strong> \u2014 the CDSCO&#8217;s ongoing digital platform development and the 2026 NDCT Rules amendments both signal a regulator moving toward efficiency and transparency alongside safety.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x2705; Practical Checklist for Pharma Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>In light of this strategic shift, buyers of Indian pharmaceutical products should:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>&#x2705; <strong>Maintain current generic sourcing relationships<\/strong> \u2014 India&#8217;s generic manufacturing base remains robust and reliable for the foreseeable future.<\/li>\n<li>&#x2705; <strong>Explore complex generic and biologic offerings<\/strong> \u2014 as Indian manufacturers expand into these segments, evaluate new suppliers against your specific therapeutic needs.<\/li>\n<li>&#x2705; <strong>Verify WHO-GMP and CDSCO compliance<\/strong> for every supplier and every product, regardless of category complexity.<\/li>\n<li>&#x2705; <strong>Monitor regulatory developments<\/strong> \u2014 the CDSCO&#8217;s digital platform initiative, NDCT reforms, and Schedule M updates all affect the quality assurance landscape.<\/li>\n<li>&#x2705; <strong>Request up-to-date documentation<\/strong> \u2014 manufacturing licenses, stability data, audit records, and product-specific approvals should be current and verifiable.<\/li>\n<li>&#x2705; <strong>Work with verified distributors<\/strong> \u2014 for a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: Pharmabiz.com (September 7, 2026) \u2014 &#8220;India must build on its strength in generics to become a global leader in complex &amp; high-value medicines&#8221;; DD India (September 7, 2026) \u2014 &#8220;India&#8217;s Pharma Sector Must Go Beyond Generics, Pursue R&amp;D and Innovation&#8221;; Express Pharma (June 9, 2026) \u2014 Piyush Goyal USD 120 billion pharma sector target by 2031. Details sourced via Google News RSS as of September 8, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content -->","protected":false},"excerpt":{"rendered":"<p>&#x1f52c; The Bigger Picture: India&#8217;s Pharma Ambition Minister Goyal&#8217;s remarks at the Bharat Health Global Expo 2026 fit within a broader pattern of government statements throughout 2026 emphasizing India&#8217;s ambition to become a comprehensive global pharmaceutical powerhouse \u2014 not just a generic drug supplier. Earlier in the year, the Minister stated that India&#8217;s pharma sector [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[48,29,49],"class_list":["post-3694","post","type-post","status-publish","format-standard","hentry","category-news","tag-generic-medicines","tag-india-pharmacy","tag-indian-pharma","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3694"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3694\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}